<DOC>
	<DOCNO>NCT01613378</DOCNO>
	<brief_summary>This multi-center , non-interventional study evaluate pattern usage clinical practice , efficacy safety tocilizumab patient rheumatoid arthritis . Patients initiated treatment tocilizumab accord licensed Canadian product monograph recommendation follow 12 month start treatment .</brief_summary>
	<brief_title>A Non-Interventional Study Rheumatoid Arthritis Patients Treated With Tocilizumab ( RoActemra/Actemra )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revise ( 1987 ) American college rheumatology ( ACR ) criterion Initiated tocilizumab treatment treat physician accordance Canadian product monograph Informed consent data subject computerize data processing Participant must fulfill reimbursement criterion treatment tocilizumab provincial private health insurance coverage Received tocilizumab prior enrolment visit Previously receive tocilizumab clinical trial compassionate use Enrolled ongoing clinical trial and/or receive treatment investigational agent within 4 week , 5 halflives investigational agent , whichever longer , start treatment tocilizumab Participation another clinical trial industry sponsor observational study History autoimmune disease joint inflammatory disease rheumatoid arthritis , exception concomitant secondary Sj√∂rgen 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>